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Abstract
Background: Chronic visceral pain is a defining symptom of many gastrointestinal disorders. The KV7 family (KV7.1–KV7.5)
of voltage-gated potassium channels mediates the M current that regulates excitability in peripheral sensory nociceptors and
central pain pathways. Here, we use a combination of immunohistochemistry, gut-nerve electrophysiological recordings in
both mouse and human tissues, and single-cell qualitative real-time polymerase chain reaction of gut-projecting sensory
neurons, to investigate the contribution of peripheral KV7 channels to visceral nociception.
Results: Immunohistochemical staining of mouse colon revealed labelling of KV7 subtypes (KV7.3 and KV7.5) with CGRP
around intrinsic enteric neurons of the myenteric plexuses and within extrinsic sensory fibres along mesenteric blood
vessels. Treatment with the KV7 opener retigabine almost completely abolished visceral afferent firing evoked by the algogen
bradykinin, in agreement with significant co-expression of mRNA transcripts by single-cell qualitative real-time polymerase
chain reaction for KCNQ subtypes and the B2 bradykinin receptor in retrogradely labelled extrinsic sensory neurons from
the colon. Retigabine also attenuated responses to mechanical stimulation of the bowel following noxious distension
(0–80mmHg) in a concentration-dependent manner, whereas the KV7 blocker XE991 potentiated such responses.
In human bowel tissues, KV7.3 and KV7.5 were expressed in neuronal varicosities co-labelled with synaptophysin and
CGRP, and retigabine inhibited bradykinin-induced afferent activation in afferent recordings from human colon.
Conclusions:We show that KV7 channels contribute to the sensitivity of visceral sensory neurons to noxious chemical and
mechanical stimuli in both mouse and human gut tissues. As such, peripherally restricted KV7 openers may represent a viable
therapeutic modality for the treatment of gastrointestinal pathologies.
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Introduction
Chronic pain associated with visceral hypersensitivity to
physiological stimuli is a hallmark of functional gastro-
intestinal (GI) disorders including irritable bowel syn-
drome (IBS). Persistent pain and decreased thresholds
to bowel distension are a function of altered neuronal
excitability of both sensitized peripheral sensory input
and maladaptive central pain processing.1
The KV7 family (KV7.1–KV7.5) of voltage-gated
potassium channels encoded by KCNQ1–5 are respon-
sible for mediating the M current and can regulate excit-
ability in a variety of central and peripheral neurons
involved in pain pathways.2–4 At thresholds below
action potential initiation and near resting membrane
potential, KV7 channels have a signiﬁcant inﬂuence on
the resting membrane potential and contribute to a mem-
brane-potential clamping eﬀect that stabilizes neuronal
excitability and acts to restrict repetitive ﬁring.4 In acute
inﬂammatory pain, Gq/11-coupled receptor-mediated
attenuation of the M current can evoke depolarization
and increased excitability of nociceptors.5 Thus, genetic
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or pharmacological inhibition of KV7 leads to increased
action potential ﬁring to excitatory stimuli, whereas KV7
openers, including the anticonvulsant drug retigabine,
produce membrane hyperpolarization and reduced excit-
ability.3,6,7 Retigabine is selective for KV7.2–7.5 over the
cardiac KV7.1 subunit and is clinically eﬃcacious in redu-
cing partial seizures in epilepsies; however, signiﬁcant cen-
trally mediated adverse eﬀects have restricted its more
widespread utility both as an anticonvulsant and putative
analgesic.8 In the periphery, enhanced KV7 channel activ-
ity has been identiﬁed as the main site of action for retiga-
bine in the attenuation of somatic inﬂammatory pain as
well as in bone cancer models where retigabine inhibits
mechanical allodynia and thermal hyperalgesia.9,10 In
addition to retigabine, tannic acid can also enhance the
M current by acting on KV7.2/KV7.3 channels in small
diameter neurons.11 Conversely, KV7 channel inhibitors
act to sensitize peripheral neurons such as XE-991, which
sensitizes C-ﬁbres to noxious heat stimulation and induces
chronic spontaneous activity of Ad ﬁbres, and camphor or
menthol, which act on KV7.2/KV7.3 expressed on cutane-
ous nerve endings.12,13 Of particular relevance to this
study is the action of inhibitory KV7 mediators under
inﬂammatory conditions, with which visceral pain is
often associated. For example, protease activated receptor
2 (PAR-2) has been implicated in mediating colonic vis-
ceral hypersensitivity and in IBS,which is characterized by
abdominal pain.14,15 In rat nociceptive sensory neurons,
PAR-2 inhibits the M current via phosphoinositide
phospholipase (PLC) activation.16 Similarly, inhibition
of Mas-related gene receptor D (MrgprD; which is
known to be up-regulated during intestinal inﬂamma-
tion17), by its ligand ß-alanine also inhibits KV7.2/KV7.3
activity.18 As such, a peripherally restricted KV7 opener
may represent a useful analgesic therapy for treating vis-
ceral pain associated with inﬂammation. Indeed when
injected into the peritoneal cavity, retigabine reduces vis-
ceral pain behaviours inmice following intracolonic appli-
cation of capsaicin;19 however, the exact site of action is
still to be resolved. Moreover, following neuropathic
injury, increased expression of repressor element 1-silen-
cing transcription factor in dorsal root ganglia (DRG)
down-regulates expression of KCNQ2 leading to neuro-
pathic hyperalgesia.20 Selective ablation of KCNQ2 from
the mouse forebrain results in visceral hyperalgesia sug-
gesting that there may also be a contribution of CNS KV7
channels to visceral pain.21Here,we sought to identify and
conﬁrm the role of peripheral KV7 channels in visceral
nociception by studying nerve ﬁbres innervating the GI
tract of both mouse and human.
KV7 channel subtype expression is tissue speciﬁc, with
KV7.1 highly expressed by cardiac myocytes
22 as well as
in epithelial23 and smooth muscle tissue,24 while KV7.2 to
KV7.5 are found in the nervous system.
25 In spinal sen-
sory pathways, rodent small diameter transient receptor
potential vanilloid subfamily type 1-positive nociceptors
express KV7.2, KV7.3 and KV7.5,
3 whilst retigabine can
reduce the excitability of unmyelinated peripheral human
axons.26 In the GI tract, KV7.2, KV7.3 and KV7.5 have
all been identiﬁed in the smooth muscle of mouse colon
suggesting a role in regulating gut motility.24 Whether
such motor events are additionally mediated by KV7
expression within the enteric nervous system itself
remains to be determined. With regard to the extrinsic
innervation (vagal and spinal pathways) of the GI tract,
KV7 channels regulate excitability in the predominantly
non-nociceptive population of vagal sensory neurons
that innervates the upper gut.27 However, the contribu-
tion of KV7 channels to the excitability of nociceptive
sensory neurons innervating the colon is unknown.
Therefore, the aims of this study were to (1) determine
the expression of KV7.3 and KV7.5 subtypes in mouse
and human lower GI tract, (2) determine the expression
of KV7 channel subtypes in DRG sensory neurons inner-
vating the lower GI tract of mouse, (3) investigate the
ability of KV7 channel opener retigabine to inhibit vis-
ceral aﬀerent excitability to acute inﬂammatory and nox-
ious stimuli (including bradykinin and mechanical
distension) and (4) validate the ability of retigabine to
attenuate human visceral aﬀerent excitability using a
novel human ex vivo model of visceral nociception.28
Materials and methods
Mouse and human tissues
Experiments were performed using male C57BL/6 mice
(10–12 weeks of age) and in accordance with the UK
Animal (Scientiﬁc Procedures) Act 1986. The collection
and use of human tissues was performed with approval
of the East London and The City HA Local Research
Ethics Committee (NREC 09/H0704/2). Fresh, non-
inﬂamed ileum (N¼ 4) and colon (N¼ 6 for immunohis-
tochemistry and N¼ 6 for electrophysiology) were
obtained under full written consent from 4 to 6 patients
(four male, median age: 58, range: 33–67 years) undergo-
ing surgery at Barts and The London NHS Trust and
Whipps Cross University Hospitals (London, UK). All
specimens were obtained from patients with non-
obstructive tumours that were not occuring in the con-
text of inﬂammatory bowel disease. Specimens were
taken with the permission of the histopathologist follow-
ing macroscopic examination and were a minimum of
10 cm away from tumour, resection margins or lymph-
atic drainage ﬁeld.
Immunohistochemistry
For sectioning studies, fresh mouse colon, as well as
human ileum and colon, were post-ﬁxed overnight
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(at 4C) in 4% paraformaldehyde. Sections (10 mm) of
cryoprotected tissue (30% sucrose w/v in 0.1 M phos-
phate-buﬀered saline (PBS)) were cut, incubated with
blocking buﬀer (Dako, UK) for 1 h, before primary
antibodies were applied overnight (4C): KV7.3 (1:500,
AP1-930, Thermo Scientiﬁc, UK), KV7.5 (1:500, PA1-
941, Thermo Scientiﬁc, UK), CGRP (1:400, ab36001,
Abcam, UK) and synaptophysin (1:200, MO776,
Dako, UK). Tissues were washed (PBS; 3 5min) and
species-speciﬁc secondary antibodies conjugated to
Alexa Fluor ﬂuorescent dyes (1:400, Thermo Fisher
Scientiﬁc, UK) applied for 1 h, before washing (PBS;
3 5min), mounting (Vectashield hard set mounting
media, Vector Laboratories, USA) and coverslipping.
For whole-mount studies, fresh mouse colon was cut
open along the mesenteric border, pinned ﬂat and ﬁxed
overnight (4C) in 4% paraformaldehyde. Following ﬁx-
ation, mucosa was removed, washed (PBS; 3 10min),
blocked (blocking buﬀer; 1 h) and incubated with pri-
mary antibodies (KV7.3, KV7.5 and CGRP; all at
1:300) for 48 h at 4C. Tissues were washed (PBS;
2 10min), and species-speciﬁc secondary antibodies
conjugated to Alexa Fluor ﬂuorescent dyes (1:200,
Thermo Fisher Scientiﬁc, UK) applied for 2 h. After a
ﬁnal wash (PBS; 3 10min), tissues were mounted (50%
glycerol in PBS) and coverslipped. Controls with no pri-
mary antibody were used in all experiments to check for
non-speciﬁc secondary antibody binding. A Leica
DM4000 epiﬂuorescence microscope was used to visual-
ize immunoreactivity of sections while whole mounts
were examined with a Zeiss LSM710 confocal micro-
scope. CGRP is commonly used as a marker of spinal
sensory aﬀerents29,30 and is a nociceptive marker in
rodents.31 At present, there is no biochemical marker
that can distinguish between intrinsic and extrinsic neu-
rons in the GI tract. Intrinsic CGRP expression has been
shown in some species where colchicine has been used to
sequester CGRP,32 while others have demonstrated
extrinsic CGRP33 and used it as a marker of extrinsic
ﬁbres showing co-labelling with TRPA134 and TRPV4.35
KCNQ subunit expression by single-cell qualitative
real-time polymerase chain reaction in colonic sensory
neurons
Sensory neurons innervating the distal colon of mouse
were labelled with Fast Blue, individually harvested and
collected for single-cell qualitative real-time polymerase
chain reaction (qRT-PCR) of KCNQ subunits as previ-
ously described in literature.36 In brief, 6 to 8 injections
(0.2 ml each) of retrograde neuronal tracer Fast Blue
(2% in saline; polysciences GmbH) were injected into
the wall of the distal colon under anesthetic (isoﬂurane;
4% induction and 1.5% maintenance) via laparotomy.
Three to ﬁve days after recovery, thoracolumbar
(TL; T10-L1) and lumbosacral (LS; L6-S1) DRG were
removed and enzymatically dissociated as described
previously in literature.36 Brieﬂy, dissected ganglia were
washed in PBS and incubated in Lebovitz L-15
Glutamax (Invitrogen) media containing 6mg/ml
bovine serum albumin (Sigma-Aldrich) and 1mg/ml col-
lagenase type 1A (Sigma-Aldrich) for 15min at 37C
(in 5% CO2). Ganglia were subsequently incubated in
L-15 media containing 1mg/ml trypsin (Sigma-Aldrich)
and 6mg/ml bovine serum albumin for 30min. After
gentle trituration using ﬁre-polished pipettes, dissociated
cells were pelleted by centrifugation (350X g) and resus-
pended in L-15 Glutamax media containing 24mM
NaHCO3, 38mM Glucose, 2% penicillin/streptomycin
and 10% fetal bovine serum. Cells were plated onto
poly-D-lysine/laminin-coated coverslips (BD Biosciences,
UK) and incubated at 37C in 5% CO2. Individual cells
were collected by pulled glass pipette within 24 h of plat-
ing. Glass tips containing single cells or no-template bath
solution controls were collected in tubes containing 9 ml
of preampliﬁcation mastermix (5 ml CellDirect 2x reac-
tion buﬀer (Invitrogen, UK), 2.5 ml 0.2X primer/probe
mix, 0.1 ml SUPERase-in (Ambion, USA) and 0.2ml
Superscript III Reverse Transcriptase/Platinum Taq
mix (Invitrogen, UK)) in TE buﬀer (Applichem,
Germany) and subjected to thermal cycling (50C for
30min, 95C for 2min, then 21 cycles of (95C for
15 s, 60C for 4min); Bio-Rad C1000 Thermal Cycler)
to produce cDNA products. Following dilution with
91 ml TE buﬀer, TaqMan quantitative polymerase
chain assays were performed on the cDNA prod-
ucts for each gene of interest (TaqMan Assay ID:
Bdkrb2, Mm00437788_s1; KCNQ1, Mm00434640_m1;
KCNQ2, Mm00440080_m1; KCNQ3, Mm00548884_
m1; KCNQ4, Mm01185500_m1 and KCNQ5,
Mm01226041_m1; glyceraldehyde-3-phosphate dehydro-
genase, Mm99999915_g1; Applied Biosystems, USA)
using the following thermal cycle (50C for 2min, 95C
for 10min, then 40 cycles of (95C for 15 s, 60C for
1min); Bio-Rad C1000 Thermal Cycler and CFX96
Real-Time System). All single-cell reverse transcription
polymerase chain reaction products expressed glyceral-
dehyde-3-phosphate dehydrogenase, the expression of
which acted as an internal positive control, whilst bath
control samples did not. The determination of gene
expression was evaluated by quantiﬁcation cycle (Cq)
values less than the threshold of 35 being considered as
positive. Overall, the expression of genes of interest was
examined in 45 TL colonic sensory neurons (N¼ 3) and
45 LS colonic sensory neurons (N¼ 3).
Isolation of mouse and human colonic tissues
Mouse and human GI tissues were isolated, and electro-
physiological activity of nerves innervating these tissues
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recorded using previously described methods.37,38
Human tissues removed during surgical resection, and
in excess to histopathological assessment, were immedi-
ately placed in ice-cold carbogenated Krebs buﬀer
(in mM: 124 NaCl, 4.8 KCl, 1.3 NaH2PO4, 2.5 CaCl2,
1.2 MgSO4.7H2O, 11.1 glucose and 25 NaHCO3) supple-
mented with nifedipine (10 mM) and atropine (10mM) to
block smooth muscle activity. In a bespoke recording
chamber, the colonic wall was pinned mucosa-side
down, the mesenteric blood vessels supplying the
gut wall were identiﬁed and the surrounding mesentery
dissected away. Mesenteric nerves running in close prox-
imity to blood vessels were identiﬁed, dissected and
isolated, and the tissue superfused with Krebs buﬀer
(7–8ml/min; 32C–34C). Mice were humanely killed
by cervical dislocation of the neck, the distal colon
gross dissected and removed along with all associated
neurovasculature. In a recording chamber, the colon
was superfused (7–8ml/min; carbogenated Krebs
buﬀer) and cannulated enabling luminal perfusion
(0.1ml/min; carbogenated Krebs buﬀer). In murine
experiments, the Krebs buﬀer was additionally supple-
mented with 3 mM indomethacin to reduce endogenous
prostanoid production. The lumbar splanchnic nerve
was identiﬁed and isolated in preparation for electro-
physiological recordings.
Extracellular electrophysiological recordings
of mouse and human afferent fibre activity
In both mesenteric nerve recordings from human tissues
and lumbar splanchnic nerve recordings from the distal
colon of mouse, isolated nerves were drawn into a boro-
silicate glass suction electrode (Harvard Apparatus, UK)
preﬁlled with Krebs buﬀer. Nerve activity was recorded
on a Neurolog headstage (Digitimer Ltd, UK), ampliﬁed
at a gain of 5000X, band pass ﬁltered (100–2000Hz) and
data acquired (20 kHz sampling rate; micro1401,
Cambridge Electronic Design, UK) to a desktop com-
puter running Spike2 (Cambridge Electronic Design,
UK) software. Action potentials were counted using an
online spike processor (Digitimer Ltd, UK), and the
threshold level for spike processing was set to the smal-
lest identiﬁable spike (typically100 mV).
Electrophysiological protocols
For all electrophysiological experiments, a minimum of
15min of baseline spontaneous activity was recorded
prior to conducting any experimental protocol. In
mouse distal colon recordings, four bradykinin (1mM)
bath superfusions (20ml) were applied at 30min inter-
vals. Prior to, and in the presence of the third consecutive
bradykinin application, retigabine (1 or 10 mM) or vehi-
cle control (0.1% dimethyl sulfoxide (DMSO)) was
applied by bath superfusion (20ml volume). In separate
experiments, phasic distension of the colon was per-
formed by blocking the luminal out-ﬂow and applying
an elevated pressure head enabling rapid increases in
intraluminal pressure (0–80mmHg). Pain behaviours
in vivo are evoked by such noxious pressures and have
been previously used to investigate colonic nociceptor
function.38 Speciﬁcally, repeat rapid phasic distensions
(0–80mmHg, 60 s at 9min intervals) were applied until
the response stabilized (typically after 5–6 distensions),
at this point increasing concentrations of retigabine were
superfused prior to, and during, every third phasic dis-
tension sequentially. In one set of experiments, responses
to 0.1mM, 1 mM and 10 mM retigabine were determined,
and in a second set of experiments, responses to 30 mM
and 100 mM retigabine were investigated. In separate
phasic distension experiments, the KV7 blocker XE991
(10 mM) was superfused prior to, and during, the sev-
enth phasic distension. In human tissues, the ability
of bradykinin to repeatedly activate human colonic
aﬀerents was investigated.39 Bradykinin (1 mM) was
applied, at an interval of 45min, in a ‘step-up’
manner where bath superfusion of 10ml of 1 mM brady-
kinin was supplemented with a direct application of
100 mM bradykinin (0.9ml) to the recording chamber.
In total, four sequential applications of bradykinin
were made in parity with murine recording protocols.
We next investigated the eﬀect of retigabine on
bradykinin-stimulated human colonic aﬀerents. During
the third repeat bradykinin application, retigabine
(100 mM) was co-applied to the bath. Following the
third bradykinin stimulation, 45min of washout
time was allowed before the fourth and ﬁnal bradykinin
stimulation.
Drugs
Stock concentrations of atropine (10mM; ethanol),
bradykinin (10mM; H20), indomethacin (3mM;
DMSO), retigabine (100mM; DMSO), XE991 (100mM;
DMSO) and nifedipine (10mM; DMSO) were all pur-
chased from Sigma Aldrich (UK) and prepared as
described. All compounds were diluted to working con-
centrations in buﬀer on the day of experimentation.
Data analysis
In multi-unit experiments, peak changes of electro-
physiological nerve activity were determined by subtract-
ing baseline ﬁring (3min before drug application) from
increases in nerve activity following nucleotide super-
fusion. The visualization of single-cell qRT-PCR expres-
sion data was created using R and the ggplot2 package.40
Statistical signiﬁcance was set at P< 0.05, and data are
displayed as mean SEM.
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Results
KV7 subtypes are expressed in neurons and
mesenteric fibres of mouse bowel tissues
GI function is regulated by a vast network of enteric
neurons organized into two plexuses: the myenteric
plexus located between the longitudinal and circular
muscle layers, and the submucosal plexus located
between the mucosa and the circular muscle. Aﬀerent
ﬁbres of extrinsic spinal sensory neurons are also present
in these tissues with projections to multiple layers of the
bowel wall. The functional KV7 heteromultimers known
to underpin neuronal M currents are combinations
of KV7.2/KV7.3 and KV7.3/KV7.5.
41–43 Thus, we ﬁrst
examined the expression of KV7.3 and KV7.5 in mouse
colonic tissues.
We hypothesized that KV7 channel subtypes were
expressed by enteric neurons, and in extrinsic sensory
ﬁbres contributing to nociception. In order to investigate
this, we performed whole-mount immunohistochemistry
against multiple KV7 channel subtypes and the sensory
neuronal marker CGRP, in separate layers of the mouse
distal colon. Immunostaining revealed both KV7.3 and
KV7.5 expression in the enteric neurons of the myenteric
plexus, which co-localized with neuronal varicosities as
identiﬁed by CGRP (Figure 1(a) and (c)). In the mesen-
tery associated with the colon, extensive punctate expres-
sion of both KV7.3 and KV7.5 was observed along
mesenteric blood vessels, which also co-expressed
CGRP (Figure 1(b) and (d)). For both KV7 subtypes,
examples of KV7-negative, CGRP-positive nerve ﬁbres
were also present (Figure 1(d)), suggesting heterogeneity
of KV7 expression. Taken together, these observations
identify KV7.3 and KV7.5 in both enteric neurons and
extrinsic sensory ﬁbres of the mouse distal colon. The
expression of KV7 by extrinsic mesenteric ﬁbres, which
are important nociceptors in the gut,44 suggests that KV7
may be involved in visceral pain pathways.
Expression of KCNQ transcripts in extrinsic sensory
neurons innervating the mouse colon
To conﬁrm the expression of KV7 channel subtypes
observed by immunohistochemistry in extrinsic sensory
ﬁbres innervating the distal colon, we performed single-
cell qRT-PCR for KCNQ1–5 transcripts in DRG neu-
rons retrogradely labelled from the mouse distal colon.
We examined individual Fast Blue-positive sensory neu-
rons harvested following primary culture of TL (T10-L1)
and LS (L6-S1) DRG, corresponding to the splanchnic
and pelvic neurons speciﬁcally innervating the distal
colon, respectively.29 In total, 15 single cells were col-
lected per spinal region (e.g., TL or LS) per mouse
(N¼ 3). In colonic sensory neurons isolated from the
TL region (representative of the splanchnic innervation),
analysis of qRT-PCR products revealed greater expres-
sion of KCNQ5 transcripts (86.7 3.8%) compared to
KCNQ2 (57.8 2.2%), KCNQ3 (42.2 2.2%) and
KCNQ4 (28.9 5.9%; Figure 2(a)). KCNQ1 transcripts
were observed infrequently (6.7 0.0%) and were only
present in one cell from each of the three animals
labelled. By contrast, colonic pelvic sensory neurons
isolated from LS DRG exhibited signiﬁcantly lower
expression of KCNQ4 transcripts (8.9 2.2%; P< 0.05,
unpaired t-test) compared to TL sensory neurons, whilst
levels of KCNQ2 (48.9 9.7%), KCNQ3 transcripts
(40.0 3.8%) and KCNQ5 (68.9 5.9%; Figure 2(a))
did not signiﬁcantly diﬀer. No LS colonic sensory
neuron expressed KCNQ1 transcripts (Figure 2(a) and
(c)). Although KCNQ5 transcripts were present in the
vast majority of TL and LS neurons investigated,
the co-expression of KCNQ2 and KCNQ3 transcripts
(as a proportion of all cells investigated) was greatest
in TL (TL, 33.3 3.8% vs. LS, 24.4 2.2%). From
this data, it is clear that KCNQ2, KCNQ3 and KCNQ5
are expressed in a large proportion of colonic sensory
neurons; however, it is diﬃcult to interpret whether dif-
ferences in TL versus LS expression proﬁles are function-
ally meaningful. Overall, however, the high expression of
KCNQ5 in extrinsic sensory neurons agrees with protein
expression data described in Figure 1. Similarly, moder-
ate expression of KCNQ3 follows the pattern of pro-
tein expressed observed in mouse colonic mesentery
(Figure 1(b)).
Co-expression of KCNQ channel subtypes with
bradykinin receptor subtype B2 in mouse colonic
sensory neurons
The algogenic peptide bradykinin is an important
endogenous inﬂammatory mediator that can activate
pain pathways by binding two G-protein coupled recep-
tor subtypes: B1 and B2. The acute eﬀects of bradykinin
are predominantly mediated by the constitutively
expressed bradykinin B2 receptors
45,46 which are capable
of altering sensory neuronal excitability by multiple
downstream intracellular pathways, including phosphor-
ylation of TRP channels,47,48 increased Ca2þ-activated
Cl conductance49 and suppression of Ca2þ-dependent
Kþ50,51 and M currents.52 In order to test the coupling of
KV7 channels to bradykinin-evoked excitation in visceral
sensory neurons, we ﬁrst examined the co-expression of
bradykinin receptor B2 (Bdkrb2) with KCNQ1–5 tran-
scripts in single-cell qRT-PCR products. In TL colonic
sensory neurons, Bdkrb2 mRNA transcripts were
observed in 64.4 5.9% of cells, and of these Bdkrb2-
positive neurons, 72.9 4.8% also expressed KCNQ2,
41.0 2.3% expressed KCNQ3 transcripts and 100.0
0.0% expressed KCNQ5 transcripts (Figure 2(b)).
Similar proportions of LS colonic sensory neurons
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expressed Bdkrb2 transcripts (64.4 12.4%); however,
co-expression with KCNQ2 (54.3 7.2%), KCNQ3
(37.4 10.4%) and KCNQ5 (85.6 7.5%) transcripts
were partially reduced compared to the TL populations
(Figure 2(c)). Of both the TL and LS colonic sensory
neurons that did express Bdkrb2 transcripts, 24% to
31% expressed transcripts for only one KCNQ subtype
(exclusively KCNQ5), the rest of Bdkrb2-positive colonic
sensory neurons co-expressed multiple KCNQ channel
subtypes, principally KCNQ3 and KCNQ5.
Retigabine inhibits bradykinin-induced afferent activa-
tion in mouse colon
We next investigated whether the opening of KV7 chan-
nels was suﬃcient to alter acute chemosensitivity to
bradykinin in peripheral terminals of sensory neurons
innervating the distal colon. Bradykinin was the chosen
chemical stimulus as activation of the B2 receptor on
sensory neurons is known to induce store release of
Ca2þ that then binds to KV7-associated calmodulin
Figure 1. Expression of KV7 channels in mouse colon and mesenteric neurovasculature. (a) KV7.3 co-expression with CGRP-positive
neurons within the myenteric plexus (MP) of mouse colon (tissue sections). Panel (iv) is a schematic representation of endings that co-label
for CGRP and KV7.3 (in black) surrounding neuronal cell bodies (in grey) of the myenteric plexus. (b) In the mesentery associated with the
colon, KV7.3 co-localizes with CGRP-positive neurons (white arrowheads) surrounding blood vessels (BV) in whole mounts. (c) KV7.5 is
expressed in the serosal layer of mouse colon and co-localizes with CGRP-positive fibres in the myenteric plexus (tissue sections). (d)
CGRP positive neurons that run alongside blood vessels found within the mesenteric attachment to the colon co-express KV7.5 (whole
mounts). Punctate staining for KV7.5 is also found around CGRP positive nerve bundle (NF). All images taken at 40X, scale bar¼ 25mm.
Figures b(iii) and d(iii) are 4X of the original images, b(i) and d(i).
LM: longitudinal muscle; CM: circular muscle.
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resulting in closure of KV7 channels and increased neur-
onal excitability.52 Speciﬁcally, multi-unit ex vivo extra-
cellular electrophysiological recordings of the lumbar
splanchnic nerve were made after cannulation of the
mouse distal colon enabling stimulation by repeat bath
superfusion of bradykinin. Application of bradykinin
(1 mM) led to an increase in aﬀerent ﬁring to 22.3 2.8
spikes/s above baseline discharge levels with a duration
of approximately 20min (N¼ 5). Repeat bradykinin
applications were made at 30min intervals. A signiﬁ-
cant desensitization in response to the second bradykinin
(1 mM) response was observed (5.4  1.21 spikes/s).
Importantly, subsequent responses to the third
(5.1 0.9 spikes/s) and fourth (6.2 1.9 spikes/s) brady-
kinin applications remained consistent in vehicle experi-
ments (P¼ 0.54, N¼ 5, repeated measures (RM) analysis
of variance (ANOVA); Figure 3(b)) enabling investiga-
tion of the eﬀect of the KV7 channel opener retigabine on
peripheral visceral aﬀerent responses to bradykinin after
the second application of bradykinin. Pre-incubation,
and co-application, of 10 mM retigabine with 1 mM
bradykinin abolished virtually all aﬀerent ﬁring (0.0
1.5 spikes/s; P< 0.05, N¼ 5, two-way RM ANOVA
with Dunnett’s post hoc). This eﬀect was completely
reversible following washout with the response to subse-
quent superfusion of 1 mM bradykinin comparable to pre-
retigabine responses (5.4 0.7 spikes/s; Figure 3(b)). In
the example trace shown in Figure 3(a), 10 mM retigabine
was additionally superfused during the washout to the
ﬁnal bradykinin application, again completely inhibiting
the elevated aﬀerent ﬁring. In separate experiments, the
application of 1mM retigabine also had an inhibitory
eﬀect on aﬀerent ﬁring to bradykinin; however, this was
smaller and did not signiﬁcantly diﬀer from vehicle con-
trols (4.0 0.6 spikes/s; P> 0.05, N¼ 5, two-way RM
ANOVA with Dunnett’s post hoc). Collectively, these
data conﬁrm that opening of KV7 reverses bradykinin-
induced action potential ﬁring in peripheral visceral aﬀer-
ent ﬁbres and highlights the importance of KV7 channels
in mechanisms underlying visceral inﬂammatory pain.
Figure 2. Expression of KCNQ and bradykinin receptor B2 (Bdkrb2) mRNA transcripts in mouse colon-projecting sensory neurones by
single-cell qRT-PCR. (a) Proportion of thoracolumbar and lumbosacral colon-projecting sensory neurons expressing transcripts for Bdkrb2,
KCNQ1, KCNQ2, KCNQ3, KCNQ4 and KCNQ5. *P< 0.05 versus TL, unpaired t-test. Co-expression analysis of Bdkrb2, KCNQ1, KCNQ2,
KCNQ3, KCNQ4 and KCNQ5 transcripts in thoracolumbar (b) and lumbosacral (c) colonic sensory neurons. Each segment represents a
single cell with a filled coloured block signifying positive expression.
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Retigabine inhibits visceral afferent sensitivity
to noxious distension
Next we investigated the ability of KV7 channels to alter
visceral mechanosensitivity in peripheral aﬀerent ter-
minals of the mouse distal colon. We applied repeat
phasic distensions (0–80mmHg for 60 s at an interval
of 9min; a pressure shown to activate all known mouse
mechanosensitive nociceptors35), to determine the eﬀect
of the KV7 channel opener retigabine on aﬀerent mech-
anoreceptors. Phasic distension led to an increase in
splanchnic nerve aﬀerent ﬁring and rapid adaptation of
the response during the 1-min distension (Figure 4(a)).
Upon relief of the pressure, ﬁring rates quickly returned
to baseline levels. As with previous studies, tachyphyl-
axis of the response to repeat distension was observed
over the subsequent distensions, with responses typically
stabilizing by the ﬁfth to sixth distension.53 Varying con-
centrations of retigabine (0.1–100 mM) were superfused
before and during the seventh distension, leading to con-
centration-dependent inhibition of the peak ﬁring rates
to subsequent phasic distension (N¼ 4–6, Figure 4(b)).
Although the response to the ﬁrst distension directly
after application of retigabine was inhibited, the max-
imal attenuation of response occurred by the third dis-
tension after application (e.g. 30min post-retigabine;
Figure 3. Retigabine inhibits bradykinin-induced afferent firing in mouse lumbar splanchnic nerve recordings. (a) Example rate histogram
with neurogram trace over time showing the effect of retigabine (10mM) on afferent excitation evoked by repeat application of bradykinin
(1mM) at 30min intervals. Repeat responses to bradykinin stabilized after initial desensitization following the first application. Retigabine
was applied prior to, and during, the third bradykinin application. The black bars indicate the duration of compound superfusion into the
bath. In this example only, retigabine (10mM) was also applied during the wash from the fourth bradykinin application to fully confirm the
ability to inhibit residual-evoked afferent excitation from bradykinin. Below, expanded traces showing action potential firing in the presence
of bradykinin (left) and in the presence of both bradykinin and retigabine (right). Below far left, example single action potential. (b) Average
change in peak firing rate to repeat application of bradykinin (1 mM) in the presence of either 1 mM or 10mM retigabine or vehicle (0.1%
DMSO) (applied during the third bradykinin). *P< 0.05 versus vehicle, repeated measures 2-way ANOVA with Dunnett’s post hoc.
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Figure 4(a)). At the concentration of retigabine (10mM)
where complete block of the bradykinin-evoked exci-
tation occurred; Figure 3(a)), there was a 48.5 3.2%
inhibition of response to noxious distension.
Application of the KV7 channel blocker XE991
(10 mM) led to a moderate increase (29.1 9.2%) in
response to noxious distension, highlighting the presence
of a tonic KV7 current during non-inﬂamed states. In
addition to regulating the response to phasic distension,
there was a trend for decreased spontaneous discharge in
the presence of retigabine (e.g. pre-retigabine, 3.89 2.52
spikes/s vs. post-retigabine 10 mM, 0.87 0.20 spikes/s,
Figure 4. Effect of retigabine on visceral afferent mechanosensitivity to phasic noxious distension. (a) Example rate histogram, intra-
luminal pressure trace and raw neurogram trace to repeat phasic distension (60 s, at 9min interval) to noxious pressures (0–80mmHg).
Retigabine was added after stabilization of the response to phasic distension (e.g., after the seventh distension) and leads to robust and
reproducible reduction in spontaneous afferent activity and evoked responses to phasic distension. Maximum effects are observed during
the third distension after application of retigabine began. In this example trace, the first three distensions are omitted, retigabine (10 mM) is
applied prior to the seventh distension and distension continued for subsequent 60 mins during washout showing almost complete reversal
of retigabine-dependent inhibition. (b) Example rate histogram, intraluminal pressure trace and raw neurogram trace to repeat phasic
distension (60 s, at 9min interval) to noxious pressures (0–80mmHg) following application of XE991 (10 mM), which increases ectopic
afferent activity and mechanically evoked afferent firing. In this example trace, the first three distensions are omitted and XE991 is applied
prior to the seventh distension. (c) Average change in response from pre-application baseline to third distension after application of
retigabine at varying concentrations (N¼ 4–6) or vehicle (0.03%–0.1% DMSO; N¼ 4) or XE991 (10mM; N¼ 3).
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N¼ 6, P¼ 0.27, paired t-test), although this was not
observable in all experiments due to very low spontaneous
discharge in some preparations. By contrast, addition of
XE991 (10mM) tended to potentiate spontaneous dis-
charge (pre-XE991, 3.70 1.10 spikes/s vs. post-XE991
10mM, 9.57 2.51 spikes/s, N¼ 5, P¼ 0.05, paired
t-test). These data suggest that KV7 channels are present
on visceral nociceptors responsive to mechanical stimuli
and that opening of KV7 channels is suﬃcient to make the
aﬀerent terminal less excitable by such stimuli.
KV7 channels are expressed in neurons of human
bowel tissue
In order to investigate the contribution of KV channels
to human GI function, we performed immunohistochem-
istry on human bowel tissues (ileum and colon).
In normal human ileum, KV7.3 expression was found
in the neuronal varicosities of the mucosal villi and
showed signiﬁcant co-expression with the neuronal
marker synaptophysin (an integral membrane protein
present in presynaptic vesicles of neurons;54
Figure 5(a)). Synaptophysin-positive nerve varicosities
also co-labelled with KV7.3 in the intracellular spaces
between villi (Figure 5(a)). In the submucosal plexus of
human ileum, KV7.3 immunostaining was punctate and
observed around the cell bodies rather than within the
neurons themselves. Structures that stained positively for
KV7.3 co-labelled with synaptophysin (Figure 5(b)) and
CGRP (Figure 6(a)). In human colon, KV7.5 expression
was observed in the lamina propria between mucosal
crypts. Structures that positively stained for KV7.5
were identiﬁed as synaptophysin-positive ﬁbres innervat-
ing the colonic mucosa (Figure 5(c)). Neuronal varicos-
ities, identiﬁed by co-expression with synaptophysin,
expressed KV7.5 in nerve ﬁbres surrounding the colonic
Figure 5. Co-localization of KV7 channels with synaptophysin in human bowel tissues. (a) KV7.3 is expressed in mucosa of human ileum,
alongside synaptophysin (Syp)-positive nerve fibres running between mucosal crypts (as outlined by dotted lines). (b) KV7.3 co-localizes
with a sub-population of synaptophysin-positive neurons in sub-mucosal ganglia (outlined by dotted lines) of ileum. (c) In human colonic
mucosa, some synaptophysin-positive neurons around crypts (outlined by dotted lines) express KV7.5. (d) KV7.5 is expressed around the
myenteric plexus (outlined by dotted lines) of human colon and co-express with synaptophysin surrounding the plexus (white arrow); 20X
objective used on a and c, 40X objective used on b and d. Scale bar: a and c¼ 20mm; b and d¼ 40mm.
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myenteric plexus (Figure 5(d)). KV7.5 also co-localized
with CGRP in the myenteric plexus suggesting expres-
sion by sensory aﬀerent pathways known to terminate at
myenteric ganglia.55 Collectively, these data identify sig-
niﬁcant expression of KV7 channels subtypes in both
intrinsic and extrinsic neuronal populations of the
human GI tract.
Retigabine inhibits bradykinin-induced afferent
activation in human colon
In order to further understand the role of KV7 channels
in human spontaneous inﬂammatory pain and to trans-
late our murine ﬁndings into man, we utilized a model of
human visceral aﬀerent activity and a similar experimen-
tal paradigm as above.28 Using surgically resected bowel
tissues, we recorded mesenteric nerve activity to repeat
application of bradykinin. A concentration of 1 mM
bradykinin was used as this has previously been shown
robustly excite human visceral aﬀerent ﬁbres in ex vivo
electrophysiological recordings.28,37 Bath superfusion of
1 mM bradykinin and a bolus of 10ml bradykinin applied
directly to the nerve under investigation led to a robust
increase in human mesenteric aﬀerent ﬁring averaging
20min in duration (Figure 7(a)). Following a washout
interval of 45min, a subsequent repeat bradykinin con-
centration was applied, although the response was partly
diminished, it did not signiﬁcantly diﬀer from the ﬁrst
(ﬁrst bradykinin, 2.14 0.30 spikes/s vs. second brady-
kinin, 1.40 0.36 spikes/s, P¼ 0.13, N¼ 7, paired t-test,
Figure 7(a)).
To investigate the role of KV7 in human visceral aﬀer-
ent sensitivity to bradykinin, we applied 100 mM retiga-
bine in the presence of the third bradykinin application.
This led to a signiﬁcant decrease of the aﬀerent response,
reducing both the duration of the overall response
(991 522 s vs. retigabine, 178 102 s) and change
in peak ﬁring (pre-retigabine, 1.40 0.36 spikes/s vs. reti-
gabine, 0.36 0.23 spikes/s, P< 0.05, N¼ 7, one-way
ANOVA with Dunnett’s post hoc) compared to the
response to bradykinin prior to retigabine being applied.
Following the washout period of 45min, bradykinin was
again applied to the bath and a partial recovery in
response to levels of aﬀerent activation comparable
to control applications was observed (retigabine vs.
post-retigabine, 0.89 0.17 spikes/s, P> 0.05, N¼ 7,
one-way ANOVA with Dunnett’s post hoc, Figure 7(b)).
Collectively, these ﬁndings demonstrate a functional role
for KV7 channels in modulating the sensitivity of periph-
eral terminals of visceral sensory neurons innervating the
human lower GI tract.
Discussion
Here we demonstrate that KV7 channel subtypes are
expressed by gut-projecting sensory neurons and that
modulation of these channels can greatly alter aﬀerent
sensitivity to mechanical and inﬂammatory stimuli. We
have shown in mouse that opening KV7 channels attenu-
ates visceral aﬀerent sensitivity to noxious distension of
the colon and to the algogenic inﬂammatory mediator
bradykinin; the latter an eﬀect that translates to human
Figure 6. Co-localization of KV7 channels with CGRP neurons in human bowel tissues. (a) Sub-mucosal plexus (SP) showing KV7.3
expressed on CGRP-positive neurons (white arrows) in human ileum. (b) KV7.5 is expressed on CGRP-positive fibres (white arrows)
within the myenteric plexus (MP) of human colon. All images taken using 40X objective. Scale bar¼ 40mm.
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visceral aﬀerents. Conversely, blockade of KV7 channels
results in hypersensitivity to mechanical stimuli. As such,
KV7/M-channel activity represents an integral regulator
of visceral aﬀerent sensitivity downstream of multiple
transduction mechanisms and is likely to contribute to
dampening of peripheral pain pathways from visceral
organs in humans.
The molecular constituents of the neuronal M current
are heteromultimeric combinations of KV7 channel sub-
types, principally KV7.2, KV7.3 and KV7.5. As a slowly
deactivating, non-inactivating sub-threshold current, the
M current exerts a stabilizing inﬂuence on neuronal
excitability, with small changes in currents capable of
signiﬁcant alterations in excitability.3,56 In the central
nervous system, mutations in KCNQ2 and KCNQ3 can
manifest as familial neonatal epilepsies with unprovoked
partial or generalized convulsions.57,58 Peripherally, KV7
channels are expressed by sensory neurons of the DRG3
and contribute to the regulation of nociceptor excitabil-
ity in models of both inﬂammatory and neuropathic
pain.3,9,16,52,59 Whilst its role in peripheral pain pathways
is well established, the contribution of KV7 in peripheral
visceral nociception and the site of action of retigabine
however remains largely unknown. Here we show in
mouse GI tissues that KV7 channel subunits (KV7.3
and KV7.5) are expressed in extrinsic sensory aﬀerents
(as identiﬁed by the presence of CGRP) associated with
blood vessels in the colonic mesentery. Such vascular
mesenteric aﬀerents are important nociceptors known
to transduce noxious stimuli including ischaemia,
inﬂammation and traction of the mesentery.44,60 We
also conﬁrm the presence of mRNA transcripts for
those subunits contributing to the M current,
including KCNQ2, KCNQ3 and KCNQ5, in the soma
of individual sensory neurons innervating the distal
colon via either the lumbar splanchnic or pelvic nerves.
By using the potent algogen bradykinin in rodent ex vivo
recordings of visceral aﬀerent activity, we show that
the KV7/M-channel opener retigabine could abolish
bradykinin-evoked responses thus supporting the
KCNQ expression observed by single-cell qRT-PCR
and immunohistochemistry in visceral nociceptors inner-
vating the colon.
We observed signiﬁcant co-expression of mRNA tran-
scripts for B2 (Brdrb2), the primary receptor responsible
for bradykinin sensitivity in visceral aﬀerents,28,45,46 with
KCNQ/M current relevant subtypes: KCNQ2, KCNQ3
and KCNQ5. Bradykinin is algogenic in human blister
Figure 7. Retigabine inhibits bradykinin-evoked afferent activation in human colon. (a) Representative recording showing human mes-
enteric afferent excitation to bradykinin (1mM); an effect that is inhibited in the presence of KV7 channel opener retigabine. Upon washout
of retigabine, bradykinin-evoked afferent excitation is recovered. Top, example rate histogram; middle, raw neurogram traces and bottom,
expanded traces showing human action potential firing during the application of bradykinin under different conditions. (b) Average
response to bradykinin before, during and after the addition of retigabine (N¼ 6). *P< 0.05 versus control, one-way ANOVA with
Bonferroni post hoc.
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base applications61 and evokes nocifensive behaviours in
rodents such as licking and paw lifting.62–64 B2 receptor-
mediated activation undergoes tachyphylaxis or desen-
sitization63,65,66 via NO-cGMP pathway and receptor
down regulation,67–69 in agreement with our observations
following sequential bradykinin application. Indeed,
bradykinin acts to depolarize and sensitize sensory noci-
ceptors via multiple downstream signalling cascades
including PKA- and PKC-dependant phosphorylation
of TRPA1,47 PKC-mediated phosphorylation of transient
receptor potential vanilloid subfamily type 1,48 reduced
Ca2þ-dependent Kþ conductance50,51 and also increased
Ca2þ activated Cl conductance.49 The latter mechanism
contributing to membrane depolarization in sensory neu-
rons due to elevated Cl concentrations driven by consti-
tutive activity of Na-K-Cl co-transporter.70,71 In addition,
bradykinin inhibits M currents in sensory neurons via a
PLC-IP3-Ca
2þ pathway.52 In the present study, the ability
of retigabine to completely suppress bradykinin-evoked
ﬁring would suggest that KV7 modulation is a critical
mechanism by which visceral aﬀerent sensitivity may be
regulated; however, it is likely that multiple rheostatic
mechanisms act in consort to enable neuronal depolariza-
tion. Indeed, opening of M channels, blockade of Ca2þ
activated Cl channels and genetic ablation of the persist-
ent sodium channel NaV1.9 are all capable of attenuating
nocifensive behaviours to intraplantar injection of brady-
kinin.52,62 As such, it is highly likely that KV7 channels
represent one mechanism by which visceral aﬀerents regu-
late ﬁring and by which retigabine is able to reduce vis-
ceral pain behaviours in mice evoked by algogens
capsaicin19 or acetic acid;21 mirroring recordings from
the saphenous nerve where retigabine blocks responses
to inﬂammatory mediators.59
Whilst bradykinin-mediated excitation is clearly
closely coupled to M current inhibition, M current
modulation is a downstream eﬀector that is utilized by
multiple extracellular signalling pathways to alter sen-
sory neuronal sensitivity to stimuli. Receptors, such as
purinergic P2Y1,2, histamine H1, bradykinin B2 and sub-
stance P NK1 are all capable of inducing PLC cascades,
which are likely to lead to inhibition of M current in
sensory neurons16 and that have well-characterized
roles in potentiating visceral pain mechanisms.72,73
Indeed, activation of PAR-2 by exogenous proteases
and mrgprD by -alanine both inhibit M current causing
depolarization leading to nociception.16,18
We also observe a strong modulatory eﬀect of KV7 on
mechanosensitivity in visceral aﬀerents with retigabine
capable of inhibiting both spontaneous discharge and
evoked ﬁring during phasic distension of the distal
colon in a concentration-dependent manner. In contrast
to saphenous recordings, peripheral nerve damage was
not required for retigabine to attenuate responses to
mechanical stimuli.59Application of XE991 led to
increased spontaneous discharge and also increased
(30%) ﬁring to distension in naı¨ve animals, suggesting
the presence of a background, and therefore suppressant,
KV7 current in these preparations. Whilst slowly adapt-
ing (C and A) mechanoreceptors innervating the paw
have been shown to be resistant to KV7 block by XE991,
rapidly-adapting (A) mechanoreceptors may alter their
ﬁring characteristics to release a volley of action poten-
tial in response to mechanical probe.59 Linopirdine, a
generic KV7 channel blocker
74 potentiates excitability
of rapidly adapting mechanoreceptors and D-hair (A)
receptors to mechanical probe; the former in a KV7.4-
dependent manner.75 This heterogeneity in KV7 function
in aﬀerents innervating the paw seems to be less relevant
to those innervating the viscera where ﬁbres are typically
less diverse in conduction velocity and ﬁbre ending
type.76,77 KV7 is likely to not only be able to modulate
neuronal responses to chemical and mechanical stimuli
but also to do so across the vast majority of aﬀerents
innervating the distal colon; a concept supported by the
signiﬁcant expression of KV7 observed by single-cell
quantitative polymerase chain. The presence of
KCNQ4 mRNA transcripts in some TL versus LS neu-
rons could imply a role in mechanosensitivity given its
association with touch sensation in mice and humans,78
although further studies are required to conﬁrm this.
Multiple ion channels have been associated with mechan-
otransduction in visceral aﬀerents, including TRP34,35 and
ASIC channels.79,80 We show that M-channel openers are
capable of inhibiting depolarizing mechanical stimuli in a
process that is likely to be independent of secondary intra-
cellular signalling cascades.
In order to translate our ﬁndings to humans, we con-
ﬁrmed expression of KV7.3 and KV7.5 in GI tissues.
Speciﬁcally, both were observed co-localizing with syn-
aptic vesicle membrane protein synaptophysin and the
neuropeptide CGRP. Synaptophysin is found within
the submucosal and myenteric plexi, longitudinal and
circular muscle and co-localizes with the pan-neuronal
marker PGP9.5.81 Therefore, co-labelling of KV7 with
synaptophysin and CGRP in human ileum and colon
indicates expression within neuronal populations either
extrinsically or intrinsically innervating the GI tract.
Interestingly, the presence of KV7 in the mucosa and
submucosal plexus of the ileum is also suggestive of a
role in chemosensing and possibly in response to inﬂam-
matory stimuli. Whilst the GI smooth muscle of the
colon expresses KV7 channels, we observed minimal
labelling in either the circular or longitudinal muscle
layers.24 Nevertheless, we cannot totally exclude the pos-
sibility that the inhibitory eﬀects of retigabine are at least
partially driven by direct activity of KV7 on smooth
muscle. Using aﬀerent recordings in human gut,28,37 we
conﬁrm that peripherally expressed KV7 channels can
modulate human colonic aﬀerent ﬁring to noxious
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stimuli. In parity to mouse recordings discussed above,
responses to repeat applications of bradykinin to the
serosal surface of the colon were signiﬁcantly attenuated
in the presence of retigabine. These build on previous
ﬁndings showing that retigabine, by increasing KV7
channel conductance, can alter excitability in isolated
human sural nerve by conﬁrming that KV7 opening
can counteract disease-relevant stimuli applied to the
native tissue with the endogenous nerve transduction
architecture in place.26
In conclusion, we show that KV7 is expressed, and
that opening of KV7 channels can inhibit chemical and
mechanical responsiveness in mouse and human colonic
aﬀerents. We also conﬁrm expression of KCNQ mRNA
in gut-projecting DRG sensory neurons from both
splanchnic and pelvic extrinsic pathways innervating
the distal colon. As such KV7 channels contribute to
modulating the excitability of aﬀerents innervating the
distal colon and are likely to be a key mechanism in
acute excitation to inﬂammatory mediators such as
bradykinin or increased sensitivity to normally innocu-
ous mechanical stimuli in pathologies where visceral
hypersensitivity is a principal symptom, such as IBS
and inﬂammatory bowel disease. Our data support the
hypothesis that a peripherally restricted KV7 channel
opener capable of limiting centrally mediated side eﬀects
may represent a therapeutic opportunity for GI disease,
especially where inﬂammation is an important compo-
nent. As such, the data presented here oﬀer promising
evidence for the usefulness of KV7 channels as novel
GI targets.
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